BufferGel
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Short-Acting
- Development Stage: Phase III
- Developer(s)/researcher(s): ReProtect Inc.
Details
- API: Carbopol 974P
- Target: Cytoplasm
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Anti-Microbial
- Regimen: On Demand
- MPT: Potential MPT
Product Status
Lead development company is inactive, and their technologies - BufferGel, Duet - do not appear to have been transferred to new development teams
History
BufferGel was originally developed at Johns Hopkins University, and intended to function primarily as an antimicrobial product for the prevention of HIV. Pre-clinical evaluation in 2001 showed contraceptive efficacy in mammals, and the gel was tested clinically in combination with a novel applicator/barrier method. In 2006, researchers proved non-inferiority to the Gynol II–diaphragm combination in a Ph III multicenter trial. Development as a combination contraceptive appears to have largely ceased following the conclusion of the trial, though BufferGel alone continued to be evaluated for STI prevention through the early 2010s.